Role of C-reactive protein as a biomarker for renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 12, 2010, Pages 1979-1989

  Saito, Kazutaka ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

biomarker; C reactive protein; kidney; kinetics; neoplasm; prognosis

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; INTERLEUKIN 2;

ALGORITHM; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; REVIEW;

ALGORITHMS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649637959     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.192     Document Type: Review

References (93)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 281(17), 1628-1631 (1999).
2. Lindblad P. Epidemiology of renal cell carcinoma. Scand. J. Surg. 93(2), 88-96 (2004).
3. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classifcation and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89(3), 604-614 (2000).
4. Zisman A, Pantuck AJ, Dorey F et al. Mathematical model to predict individual survival for patients with renal cell carcinoma. J. Clin. Oncol. 20(5), 1368-1374 (2002).
5. Fuhrman SA, Lasky LC, Limas C. Prognostic signifcance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6(7), 655-663 (1982).
6. Kattan M W, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166(1), 63-67 (2001).
7. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20(23), 4559-4566 (2002).
8. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168(6), 2395-2400 (2002).
9. Karakiewicz PI, Briganti A, Chun FK et al. Multi-institutional validation of a new renal cancer-specifc survival nomogram. J. Clin. Oncol. 25(11), 1316-1322 (2007).
10. Biomarkers Defnition Working Group. Biomarkers and Surrogate Endpoints: Preferred defnitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
11. Roxburgh CS, McMillan DC. Role of systemic infammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 6(1), 149-163 (2010).
12. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic infammation: importance of NOD2 and NALP3 in interleukin-1b generation. Clin. Exp. Immunol. 147(2), 227-235 (2007).
13. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to infammation. N. Engl. J. Med. 340(6), 448-454 (1999).
14. Dhingra R, Gona P, Nam BH et al. C-reactive protein, infammatory conditions, and cardiovascular disease risk. Am. J. Med. 120(12), 1054-1062 (2007).
15. Tillet WS, Francis TJ. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 52(4), 561-571 (1930).
16. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28, 157-183 (2010).
17. Volanakis JE, Kaplan MH. Specifcity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc. Soc. Exp. Biol. Med. 136(2), 612-614 (1971).
18. Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann. NY Acad. Sci. 762, 102-107 (1995).
19. Black S, Kushner I, Samols D. C-reactive protein. J. Biol. Chem. 279(47), 48487-48490 (2004).
20. Agrawal A, Samols D, Kushner I. Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPb to the promoter. Mol. Immunol. 40(6), 373-380 (2003).
21. van Leeuwen MA, van der Heijde DM, van Rijswijk MH et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 21(3), 425-429 (1994).
22. Nielen MM, van Schaardenburg D, Reesink HW et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 50(8), 2423-2427 (2004).
23. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an infammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J. Am. Coll. Cardiol. 32(1), 35-41 (1998).
24. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Infammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336(14), 973-979 (1997).
25. Grivennikov SI, Greten FR, Karin M. Immunity, infammation, and cancer. Cell 140(6), 883-899 (2010).
26. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related infammation. Nature 454(7203), 436-444 (2008).
27. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related infammation. J. Leukoc. Biol. 86(5), 1065-1073 (2009).
28. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev. 15(2), 381-384 (2006).
29. McMillan DC, Preston T, Watson WS et al. Relationship between weight loss, reduction of body cell mass and infammatory response in patients with cancer. Br. J. Surg. 81(7), 1011-1014 (1994).
30. Falconer JS, Fearon KC, Ross JA et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75(8), 2077-2082 (1995).
31. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the infammatory response in cancer patients. Nutr. Cancer 31(2), 101-105 (1998).
32. O'Gorman P, McMillan DC, McArdle CS. Longitudinal study of weight, appetite, performance status, and infammation in advanced gastrointestinal cancer. Nutr. Cancer 35(2), 127-129 (1999).
33. Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and infammatory markers in advanced pancreatic cancer. Nutr. Cancer 35(2), 106-110 (1999).
34. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br. J. Cancer 79(3-4), 495-500 (1999).
35. Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 69(4), 491-497 (1980).
36. Graf W, Bergstrom R, Pahlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur. J. Cancer 30A(4), 453-457 (1994).
37. Maltoni M, Caraceni A, Brunelli C et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J. Clin. Oncol. 23(25), 6240-6248 (2005).
38. McMillan DC. An infammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc. Nutr. Soc. 67(3), 257-262 (2008).
39. Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic infammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer. 92(4), 625-627 (2005).
40. Yoshida S, Saito K, Koga F et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 101(8), 978-981 (2008).
41. Saito K, Kawakami S, Ohtsuka Y et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 100(2), 269-273 (2007). (Pubitemid 47036572)
42. Miki S, Iwano M, Miki Y et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250(2), 607-610 (1989).
43. Takenawa J, Kaneko Y, Fukumoto M et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J. Natl Cancer Inst. 83(22), 1668-1672 (1991).
44. Koo AS, Armstrong C, Bochner B et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol. Immunother. 35(2), 97-105 (1992).
45. Oya M, Takayanagi A, Horiguchi A et al. Increased nuclear factor-kB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 24(3), 377-384 (2003).
46. Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52(12), 3317-3322 (1992).
47. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic infammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 72(3), 424-430 (1997).
48. Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J. Urol. 148(6), 1778-1781 (1992).
49. Verma S, Yeh ET. C-reactive protein and atherothrombosis-beyond a biomarker: an actual partaker of lesion formation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285(5), R1253-R1256 (2003).
50. Kawai Y, Matsuyama H, Korenaga Y et al. Preoperative erythrocyte sedimentation rate is an independent prognostic factor in Japanese patients with localized clear cell renal cell carcinoma. Urol. Int. 83(3), 306-310 (2009).
51. Lee SE, Byun SS, Han JH, Han BK, Hong SK. Prognostic signifcance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int. 98(6), 1228-1232 (2006).
52. Sengupta S, Lohse CM, Cheville JC et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer 106(2), 304-312 (2006).
53. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur. J. Clin. Invest. 26(6), 427-435 (1996).
54. Kimura M, Tomita Y, Imai T et al. Signifcance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer 92(8), 2072-2075 (2001).
55. Ramankulov A, Lein M, Johannsen M et al. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett. 269(1), 85-92 (2008).
56. Paret C, Schon Z, Szponar A, Kovacs G. Infammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur. Urol. 57(5), 859-866 (2010).
57. Thiounn N, Pages F, Flam T et al. IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol. Lett. 58(2), 121-124 (1997).
58. Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J. Clin. Oncol. 22(12), 2371-2378 (2004).
59. Arend WP, Malyak M, Smith MF Jr et al. Binding of IL-1 a, IL-1 b, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fuids. J. Immunol. 153(10), 4766-4774 (1994).
60. May LT, Viguet H, Kenney JS, Ida N, Allison AC, Sehgal PB. High levels of 'complexed' interleukin-6 in human blood. J. Biol. Chem. 267(27), 19698-19704 (1992).
61. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J. Clin. Immunol. 28(1), 1-13 (2008).
62. Satomi Y. [A clinical study of the prognosis of renal carcinoma-with reference to factors on the part of host]. Nippon Hinyokika Gakkai Zasshi 64(3), 195-216 (1973).
63. Masuda H, Kurita Y, Suzuki A, Kanbayashi T, Suzuki K, Fujita K. Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int. J. Urol. 4(3), 247-253 (1997). (Pubitemid 127494960)
64. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 99(1), 77-80 (2007).
65. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic infammatory response and cancer-specifc survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 94(6), 781-784 (2006).
66. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic infammatory response, prognostic scoring systems and relapse-free and cancer-specifc survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 101(8), 959-963 (2008).
67. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 13(11), 1365-1370 (2006).
68. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J. Natl Cancer Inst. 95(9), 634-635 (2003).
69. Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specifc mortality: a European study of 313 patients. Cancer 110(6), 1241-1247 (2007).
70. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19(6), 1649-1657 (2001). (Pubitemid 32230864)
71. Johnson TV, Abbasi A, Owen-Smith A, et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the frst year following potentially curative nephrectomy for clear cell renal cell carcinoma. J. Urol. 183(2), 480-485 (2010).
72. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 247(18), 2543-2546 (1982).
73. Vogl UM, Zehetgruber H, Dominkus M, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br. J. Cancer 95(6), 691-698 (2006).
74. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic infammatory response, performance status and survival in patients undergoing a-interferon treatment for advanced renal cancer. Br. J. Cancer 91(7), 1236-1238 (2004).
75. Casamassima A, Picciariello M, Quaranta M et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy J. Urol. 173(1), 52-55 (2005).
76. Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 57(2), 317-325 (2010).
77. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-a as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
78. Blay JY, Negrier S, Philip T, Favrot M, Mercatello A. Pretreatment serum CRP and response to interleukin 2. Br. J. Cancer 69(1), 200-201 (1994).
79. Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M. Clinical outcome of combined immunotherapy with interferon-a and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol. Oncol. 27(6), 598-603 (2009).
80. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wil T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 1, CD001425 (2005).
81. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer 88(3), 348-353 (2003).
82. McMillan DC. Systemic infammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 12(3), 223-226 (2009).
83. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an infammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br. J. Cancer 94(5), 637-641 (2006).
84. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an infammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 6(5), 450-453 (2006).
85. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an infammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br. J. Cancer 90 (9), 1704-1706 (2004).
86. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an infammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br. J. Cancer 94(2), 227-230 (2006).
87. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an infammation-based prognostic score in patients with metastatic renal cancer. Cancer 109(2), 205-212 (2007).
88. Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classifcation: the TNM-C score. J. Urol. 181(3), 1004-1012 (2009).
89. Johnson TV, Abbasi A, Owen-Smith A et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology 76(3), 766.e1-e5 (2010).
90. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J. Urol. 180(2), 515-519 (2008).
91. Shinohara N, Kumagai A, Kanagawa K et al. Multicenter Phase II trial of combination therapy with meloxicam, a Cox-2 inhibitor, and natural interferon-a for metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 39(11), 720-726 (2009).
92. Ramsey S, Aitchison M, Graham J, McMillan DC. The longitudinal relationship between the systemic infammatory response, circulating T-lymphocytes, interleukin-6 and-10 in patients undergoing immunotherapy for metastatic renal cancer. BJU Int. 102(1), 125-129 (2008).
93. Saito K, Tatokoro M, Fujii Y et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur. Urol. 55(5), 1145-1153 (2009).